Hemogenyx Pharmaceuticals PLC Presentation at the American Society of Hematology
2020年10月19日 - 3:00PM
RNSニュース (英語)
TIDMHEMO
Hemogenyx Pharmaceuticals PLC
19 October 2020
October 19, 2020
Hemogenyx Pharmaceuticals plc
("Hemogenyx Pharmaceuticals" or the " Company " )
Presentation at the American Society of Hematology Meeting
Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce
its participation in this year's American Society of Hematology
(ASH) meeting and exposition, taking place December 5-8, 2020.
Scientists from the Company will present a poster entitled "
FLT3-CD3 Bispecific Antibody Specifically Eliminates Normal
Hematopoietic Progenitors and AML in Humanized Mouse Models " in
this year's conference, which will be taking place virtually due to
the COVID-19 pandemic. The poster will be presented within the
session "Acute Myeloid Leukemia: Novel Therapy, excluding
Transplantation: Poster III" on Monday, December 7, 2020.
The Virtual Poster Hall will be open for attendees to browse a
different set of posters each day. In addition to the presentation,
the Company's abstract will also be published online in the
November supplemental issue of "Blood". First publication of the
abstract will be in the online meeting program on November 5, 2020,
at 9 a.m. EST.
The Company's bispecific antibody therapy has shown promising
results both in vitro and in vivo preclinical experiments and
displays advantages over current standard of care treatments for
AML due to its increased specificity and efficacy, underscoring the
Company's commitment to breakthrough therapies for the treatment of
blood diseases.
The ASH meeting
(https://www.hematology.org/meetings/annual-meeting) is the world's
most comprehensive hematology event of the year that provides an
invaluable educational experience to its participants and the
opportunity to review thousands of scientific abstracts
highlighting updates on the most critical topics in hematology.
Enquiries:
Hemogenyx Pharmaceuticals plc https://hemogenyx.com
Dr Vladislav Sandler, Chief Executive headquarters@hemogenyx.com
Officer & Co-Founder
Peter Redmond, Director peter.redmond@hemogenyx.com
SP Angel Corporate Finance LLP Tel: +44 (0)20 3470
0470
Matthew Johnson, Vadim Alexandre,
Soltan Tagiev
Peterhouse Capital Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey, Charles
Goodfellow
About Hemogenyx Pharmaceuticals plc
Hemogenyx Pharmaceuticals is a publicly traded company (LSE:
HEMO) headquartered in London, with its US operating subsidiaries,
Hemogenyx LLC and Immugenyx LLC, located in New York City at its
state-of-the-art research facility.
The Company is a pre-clinical stage biopharmaceutical group
developing new medicines and treatments to bring the curative power
of bone marrow transplantation to a greater number of patients
suffering from otherwise incurable life-threatening diseases.
Hemogenyx Pharmaceuticals is developing several distinct and
complementary product candidates, as well as a platform technology
that it uses as an engine for novel product development.
For more than 50 years, bone marrow transplantation has been
used to save the lives of patients suffering from blood diseases.
The risks of toxicity and death that are associated with bone
marrow transplantation, however, have meant that the procedure is
restricted to use only as a last resort. The Company's technology
has the potential to enable many more patients suffering from
devastating blood diseases such as leukemia and lymphoma, as well
as severe autoimmune diseases such as multiple sclerosis, aplastic
anemia and systemic lupus erythematosus (Lupus), to benefit from
bone marrow transplantation.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAMRBRTMTTBMAM
(END) Dow Jones Newswires
October 19, 2020 02:00 ET (06:00 GMT)
Silver Falcon (LSE:SILF)
過去 株価チャート
から 5 2024 まで 6 2024
Silver Falcon (LSE:SILF)
過去 株価チャート
から 6 2023 まで 6 2024